ArticleScientific reports2025
Synthesis and evaluation of nitrochromene derivatives as potential antileishmanial therapeutics through biological and computational studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structural analysis of ITS 1 gene ofFrontiers in cellular and infection microbiology · 2026Article
- Comprehensive Computational Study of a Novel Chromene-Trione Derivative Bioagent: Integrated Molecular Docking, Dynamics, Topology, and Quantum Chemical Analysis.International journal of molecular sciences · 2025Article
- Evaluation of the Antileishmanial Activity of Some Benzimidazole Derivatives Using In Vitro and In Silico Techniques.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a parasitic disease caused by protozoan organisms belonging to the Leishmania genus, affecting many individuals worldwide, with the burden surpassing one million cases. This disease leads to considerable morbidity and mortality, predominantly within tropical and subtropical regions. The current therapeutic options for leishmaniasis are far from ideal, as they fail to achieve a level of efficacy that can be deemed universally effective. The primary drawbacks of existing treatments include severe side effects, substantial toxicity, high financial costs, extended treatment regimens, and the discomfort associated with injectable forms of administration. Additionally, the growing issue of drug resistance presents a formidable challenge, further complicating disease management and control efforts. In light of these limitations, developing new therapeutic agents that can effectively disrupt the parasite's life cycle at multiple stages is of paramount importance. This study endeavors to address this critical need by focusing on the design and synthesis of a series of novel compounds. Fifteen derivatives incorporating the nitrochromene pharmacophore were meticulously synthesized using the Henry reaction. After synthesizing these derivatives, a comprehensive evaluation of their biological activity against L. tropica was undertaken. This assessment employed both in vitro techniques to directly observe the compounds' effects on the parasite and in silico methods, specifically molecular docking studies, to predict and analyze the interaction between the synthesized compounds and various target proteins of the parasite. The dual approach of combining experimental and computational methods aims to provide a robust understanding of the compounds' mechanisms of action and their potential as effective anti-leishmanial agents. This integrative strategy not only enhances the reliability of the findings but also offers valuable insights that could guide future drug development efforts in combating leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.